Biocon Biologics has settled patent disputes with Bayer Inc and Regeneron Pharmaceuticals Inc, enabling the launch of Yesafili, an ophthalmology product for neovascular and age-related macular degeneration, in Canada by July 1, 2025.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/YGviHOK
via IFTTT
Home »
Healthcare/Biotech-Industry-Economic Times
» Biocon Biologics settles patent issue; paves way for launch of biosimilar product in Canada
0 comments:
Post a Comment